- Home
- PRE vs CRDF Comparison
PRE vs CRDF Comparison
Compare PRE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRE
- CRDF
- Stock Information
- Founded
- PRE 2014
- CRDF 1999
- Country
- PRE Hong Kong
- CRDF United States
- Employees
- PRE N/A
- CRDF N/A
- Industry
- PRE Biotechnology: Laboratory Analytical Instruments
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRE Industrials
- CRDF Health Care
- Exchange
- PRE Nasdaq
- CRDF Nasdaq
- Market Cap
- PRE 131.3M
- CRDF 144.4M
- IPO Year
- PRE N/A
- CRDF N/A
- Fundamental
- Price
- PRE $15.87
- CRDF $2.24
- Analyst Decision
- PRE Buy
- CRDF Strong Buy
- Analyst Count
- PRE 1
- CRDF 5
- Target Price
- PRE $9.00
- CRDF $11.10
- AVG Volume (30 Days)
- PRE 149.0K
- CRDF 859.8K
- Earning Date
- PRE 11-26-2025
- CRDF 11-06-2025
- Dividend Yield
- PRE N/A
- CRDF N/A
- EPS Growth
- PRE N/A
- CRDF N/A
- EPS
- PRE N/A
- CRDF N/A
- Revenue
- PRE $57,051,000.00
- CRDF $545,000.00
- Revenue This Year
- PRE $202.46
- CRDF N/A
- Revenue Next Year
- PRE $103.60
- CRDF N/A
- P/E Ratio
- PRE N/A
- CRDF N/A
- Revenue Growth
- PRE 151.74
- CRDF N/A
- 52 Week Low
- PRE $3.10
- CRDF $1.90
- 52 Week High
- PRE $16.98
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- PRE 69.77
- CRDF 49.79
- Support Level
- PRE $13.07
- CRDF $2.20
- Resistance Level
- PRE $14.89
- CRDF $2.46
- Average True Range (ATR)
- PRE 1.18
- CRDF 0.12
- MACD
- PRE -0.05
- CRDF 0.04
- Stochastic Oscillator
- PRE 75.68
- CRDF 52.08
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.